In her Senate Finance Committee hearing today, USTR-nominee Katherine Tai stated, "the Biden administration itself is committed to a holistic review of China and the US-China strategy."
Good. In a new paper, I too reviewed US-China strategy.
US-China trade war average tariffs:
• US tariff on China went from 3% to 19.3%
• China's tariff on US exports went from 8% to 20.7%
Trump did get China to liberalize - just toward everyone else, not the US:
• China cut its tariff toward rest of world from 8% to 6.1%
2/
Despite the Phase One agreement, US tariffs on China remain in effect, covering $335 billion of imports from China.
US tariffs remain on a lot of intermediate inputs, raising costs to US businesses and their workers...
3/
Despite the Phase One agreement, China's tariffs technically remain in effect, covering $90 billion of imports from the United States.
If someone in China wants to import from the US, there is a separate tariff exemption process run by its Ministry of Finance... 4/
In 2018, Trump administration set up an opaque "product exclusion" process for companies to beg for an exemption from tariffs on China.
We now have estimates for how much imports they excluded (4% of tariffed products) and how much US tariff revenue was foregone ($8.3 bn)... 5/
Trade Remedies!!!
Fear not! US antidumping and countervailing duties continued on their upward trend during the Trump administration.
US antidumping duties covered 7.4% of imports from China at the end of 2016, increasing to 10.3% by end of 2020...
6/
US-China trade war tariffs: What if you throw in...
• Antidumping – the average tariff goes up (by A LOT in the US case)
• Product exclusions – the average tariff goes down a bit
7/
Oof! By the end of the Trump administration, you are left with A LOT of overlapping US tariffs on China.
I.e., many products being hit with MULTIPLE special tariffs all at once.
Take Steel: Antidumping duties! Section 232 national security tariffs!! Section 301 tariffs!!!
8/
In late 2019, China agreed to buy tens of billions of dollars of additional US exports in 2020 under Trump's Phase One deal.
That didn't happen...
9/
MANUFACTURING: Trump cast his trade war as designed to help US manufacturing.
US manufacturing exports to China had nearly doubled 2009-17. The trade war put an end to that.
And in the first year of Phase One, manufacturing continued to suffer, declining another 5%...
10/
AGRICULTURE: Amazing! It got back to 2017 levels. But Ag exports...
• ended up 18% short of the 2020 legal commitment
• FAR lower than Trump's deal (see Annex 6-1 footnote b) wanted - ie, China would “strive” to buy $5bn more per year ON TOP OF the unmet commitments...
11/
ENERGY: The commitments themselves were a puzzle
And those exports performed the worst of the three goods sectors, reaching less than 40% of the 2020 legal commitment...
12/
The paper has more, including
• export controls!
• withhold release orders!
• reclassification of Hong Kong!
Most importantly, find **ALL THE DATA** organized to conduct your own (better!!!) research and holistic review of US-China strategy.
In my 10 years as a professor, I struggled to find material on contemporary policy issues for my SYLLABUS.
The speed & novelty of today's policy changes impacting trade make the challenge **YOU** face even greater.
Here is a small attempt to help... 1/🧵
Here are four (IV) papers. Each...
• contains a positive explanation of what happened
• leans heavily (and makes available) data
• admittedly raises more questions than it answers
(though, since the policy issues remain unresolved, perhaps that is a feature, not a bug...) 2/
I. COVID-19 VACCINES: How dozens of companies at nearly 100 geographically distributed sites came together to form supply chains to manufacture billions of doses from Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, and CureVac... 3/
CureVac's COVID-19 mRNA vaccine may not be salvageable. However, the company's brand new manufacturing supply chain - capable of delivering 1 billion doses - should be. But doing so requires creative industry / policymaker collaboration.
On April 15, CureVac had announced its supply chain was on track to manufacture 300 million doses of its mRNA vaccine by the end of 2021 and another 1 billion doses in 2022, upon regulatory approval.
How in the world did we end up with billions of doses of COVID-19 vaccines manufactured by Pfizer/ BioNTech, Moderna, AstraZeneca, and Johnson & Johnson?
Roughly 4 billion doses of COVID-19 vaccines have now been administered worldwide. Most required a two-dose regimen—if that trajectory continued, close to 14 billion shots would be needed to inoculate the global population. 2/
Getting a new vaccine from beginning to end — from concept to delivering shots into the public’s arms — requires five steps associated with five, largely separable, sets of fixed costs. 3/
COVID-19 meant devastating shortages of personal protective equipment (PPE), like masks, gowns and gloves. What happened to trade, the unprecedented trade and industrial policy to emerge, as well as lessons learned for future preparedness.
Chip shortage! The Biden administration and US allies have now committed to work together on semiconductor policy. That will prove hard. Why it's needed, and where to start.
The chip shortage facing automakers heightened the issue's seriousness. But the supply of semiconductors was at risk long before the pandemic, and COVID-19 is only partly to blame for today’s problems.
One of the biggest culprits was a sudden shift in US trade policy... 2/
Trump imposed 25% trade war tariffs on semiconductors beginning in July 2018. The US now imports **half as many** semiconductors from China as it did pre-trade war. (That's billions of fewer chips).
Those missing chips have NOT been replaced by imports from elsewhere... 3/
March: White House and European Commission set up a liaison between Jeffrey Zients and Thierry Breton to help overcome input shortages facing vaccine makers on both sides of the Atlantic... 2/10
April: CureVac CEO complains about lack of access to inputs, blaming the Defense Production Act:
“Be it chemicals, equipment, filters or hoses: US manufacturers are obliged first to meet American demand, and that means we are slipping down the list” 3/10